Efforts to design an effective antibody-based vaccine against HIV-1 would benefit from understanding how germ-line B-cell receptors (BCRs) recognize the HIV-1 gp120/gp41 envelope spike. Potent VRC01-like (PVL) HIV-1 antibodies derived from the VH1-2*02 germ-line allele target the conserved CD4 binding site on gp120. A bottleneck for design of immunogens capable of eliciting PVL antibodies is that VH1-2*02 germ-line BCR interactions with gp120 are uncharacterized. Here, we report the structure of a VH1-2*02 germ-line antibody alone and a germ-line heavy-chain/mature light-chain chimeric antibody complexed with HIV-1 gp120. VH1-2*02 residues make extensive contacts with the gp120 outer domain, including all PVL signature and CD4 mimicry inter...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
Background: The most effective way to control the AIDS epidemic would be through active vaccination....
SummaryElicitation of broadly neutralizing antibodies remains a long-standing goal of HIV vaccine re...
Efforts to design an effective antibody-based vaccine against HIV-1 would benefit from understanding...
A large number of anti–HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glyco...
Background: A large number of anti-HIV-1 antibodies targeting the CD4 binding site (CD4bs) on gp12...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
Following infection by HIV-1, the host immune response is unable to clear the virus due to a variet...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
A large number of anti–HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glyco...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
Background: The most effective way to control the AIDS epidemic would be through active vaccination....
SummaryElicitation of broadly neutralizing antibodies remains a long-standing goal of HIV vaccine re...
Efforts to design an effective antibody-based vaccine against HIV-1 would benefit from understanding...
A large number of anti–HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glyco...
Background: A large number of anti-HIV-1 antibodies targeting the CD4 binding site (CD4bs) on gp12...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
Following infection by HIV-1, the host immune response is unable to clear the virus due to a variet...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
A large number of anti–HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glyco...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
Background: The most effective way to control the AIDS epidemic would be through active vaccination....
SummaryElicitation of broadly neutralizing antibodies remains a long-standing goal of HIV vaccine re...